44 min ago | BioSpace
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Stefan Oschmann came courting biotechnology start-ups last week, a trans-Atlantic visitor promising not only pharmaceutical industry expertise but also cash.
4 hrs ago | WHTC
Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
8 hrs ago | The Hartford Courant
Forest Laboratories Inc said Howard Solomon, its chief executive of more than 35 years, will retire at the end of this year, capping a tenure that saw the company morph from a small generic and vitamins maker to a $10 billion corporation.
Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business.
BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.
Drowning was the most common cause of death associated with the Oct. 29 Superstorm Sandy, according to a new report out Thursday from Centers for Disease Control and Prevention.
A federal panel of medical experts said that an experimental insomnia drug from Merck & Co.
Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.
A report by the Centers for Disease Control and Prevention is showing a big drop in teen birth rates that some experts say is startling.
Drugmaker Pfizer Inc. plans to try to sell its controlling stake in its former animal health business, Zoetis Inc., through a voluntary stock exchange with Pfizer shareholders.
Pesticide makers have taken to framing themselves as stewards of the bees as backlash over their products' links to mass bee deaths grows.
Once perceived as harmless, phthalates have come under increasing scrutiny. A growing collection of evidence suggests dietary exposure to phthalates may cause significant metabolic and hormonal abnormalities, especially during early development.
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
Faced with manufacturing quality questions that caused the FDA to reject its potential Parkinson's disease treatment, Impax Laboratories has hired a committee of specialists to oversee quality improvements at its California facility.
Apple's ability to shelter billions of dollars of income from tax has depended on an unusual loophole in the Irish tax code that helps the country compete with other countries for investment and jobs.